Adage Capital Partners’s Silence Therapeutics SLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLN
SL
Adage Capital Partners's SLN Position: Q3 2026 in Review
Adage Capital Partners opened a new position in Silence Therapeutics (SLN) in Q3 2026: 130,000 shares worth $1.42M. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in SLN as recently as Q3 2024.
Adage Capital Partners first reported a position in SLN in Q1 2021 and has held it in 12 quarters since. The position peaked at $13.1M in Q4 2021. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.
- Adage Capital Partners held 130,000 shares of Silence Therapeutics worth $1.42M as of Q3 2026.
- Silence Therapeutics was a new Adage Capital Partners position in Q3 2026.
- Silence Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q3 2026, its #917 holding.
- Adage Capital Partners first reported a position in Silence Therapeutics in Q1 2021 and has held it in 12 quarters since.
- Adage Capital Partners's Silence Therapeutics position peaked at $13.1M in Q4 2021.
- 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.